CapsoVision vs Iridex
CV and IRIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CV and IRIX compare
CapsoVision is the larger company, worth 25 times as much as Iridex ($314M against $12.5M).
CapsoVision grew revenue faster over the last twelve months (6.4% versus 3.7% for Iridex).
Iridex keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −210% at CapsoVision.
Iridex scores higher on the StockData Score (7 against 6 for CapsoVision), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CV | IRIX |
|---|---|---|
| Size and price | ||
| Market cap | $314M | $12.5M |
| Share price | $6.27 | $0.710 |
| Change, 1 year | 15.2% | −40.4% |
| Change, 5 years | – | −90.7% |
| Beta (5Y) | −1.09 | 0.94 |
| Employees | 99 | 93 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.5× | 0.2× (better) |
| P/B | 11.9× | 3.4× (better) |
| FCF yield | −9.3% (better) | −16.0% |
| Fair value | $1.28 | – |
| Margin of safety | −391% | – |
| Growth | ||
| Revenue growth (TTM) | 6.4% (better) | 3.7% |
| Revenue growth, 5Y average | – | 7.7% |
| Profitability | ||
| Gross margin | 49.7% (better) | 35.9% |
| Operating margin | −212% | −5.4% (better) |
| Net margin | −210% | −6.9% (better) |
| FCF margin | −210% | −3.9% (better) |
| Return on equity | −125% | −73.1% (better) |
| Return on invested capital | −99.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.07 (better) | 1.82 |
| Altman Z-score | 20.27 (better) | −2.49 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 10.2% | 12.4% |
| Held by insiders | 29.0% | 76.1% |
| Insider net buying, 12 months | $21.0M (better) | $536K |
| Short interest, % of float | 5.5% | 0.94% |
Go deeper
- CV stock overview
- CV income statement
- CV valuation and score
- IRIX stock overview
- IRIX income statement
- IRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.